

Alfonso Piciocchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1748438/publications.pdf>

Version: 2024-02-01

154
papers

4,030
citations

109264

35
h-index

133188

59
g-index

155
all docs

155
docs citations

155
times ranked

5513
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 252-257.	3.3	314
2	Dasatinib+Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine, 2020, 383, 1613-1623.	13.9	279
3	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood, 2019, 134, 935-945.	0.6	148
4	Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplantation, 2015, 50, 282-288.	1.3	142
5	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 872-880.	2.0	141
6	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. Journal of Clinical Oncology, 2013, 31, 2671-2677.	0.8	121
7	Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood, 2010, 115, 3776-3786.	0.6	109
8	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. American Journal of Hematology, 2014, 89, 480-486.	2.0	104
9	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2009, 15, 5002-5007.	3.2	103
10	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	2.9	103
11	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. American Journal of Hematology, 2015, 90, E80-5.	2.0	93
12	Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 trial). European Journal of Haematology, 2014, 92, 527-536.	1.1	90
13	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology, 2015, 171, 239-246.	1.2	80
14	Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood, 2014, 123, 2378-2388.	0.6	78
15	PML-RAR kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia, 2016, 30, 1987-1992.	3.3	75
16	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica, 2016, 101, 1544-1552.	1.7	72
17	Clinical features and prognostic factors in solitary plasmacytoma. British Journal of Haematology, 2016, 172, 554-560.	1.2	69
18	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2017, 130, 99-99.	0.6	63

#	ARTICLE	IF	CITATIONS
19	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014, 28, 642-648.	3.3	57
20	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1080-1088.	2.0	54
21	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	1.7	54
22	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021, 106, 1559-1568.	1.7	49
23	<i>NOTCH1</i> , <i>SF3B1</i> , <i>BIRC3</i> and <i>TP53</i> mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , 2014, 55, 2785-2792.	0.6	47
24	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017, 28, 1547-1553.	0.6	46
25	Spinal Nerves Schwannomas: Experience on 367 Cases—Historic Overview on How Clinical, Radiological, and Surgical Practices Have Changed over a Course of 60 Years. <i>Neurology Research International</i> , 2017, 2017, 1-12.	0.5	46
26	Rapid identification of <i>BCR/ABL</i> like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i> , 2018, 181, 642-652.	1.2	46
27	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. <i>Blood</i> , 2018, 132, 405-412.	0.6	46
28	Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. <i>Haematologica</i> , 2010, 95, 1114-1121.	1.7	45
29	Management of carbapenem resistant <i>Klebsiella pneumoniae</i> infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. <i>Haematologica</i> , 2015, 100, e373-e376.	1.7	44
30	Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification. <i>Blood</i> , 2015, 126, 81-81.	0.6	44
31	Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. <i>Leukemia and Lymphoma</i> , 2014, 55, 270-275.	0.6	43
32	Patient-reported outcomes in randomised controlled trials of gynaecological cancers: Investigating methodological quality and impact on clinical decision-making. <i>European Journal of Cancer</i> , 2014, 50, 1925-1941.	1.3	41
33	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. <i>Leukemia Research</i> , 2016, 41, 36-42.	0.4	41
34	Role of <i>BCL2L10</i> methylation and <i>TET2</i> mutations in higher risk myelodysplastic syndromes treated with 5-Azacitidine. <i>Leukemia</i> , 2011, 25, 1910-1913.	3.3	40
35	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 20520-20531.	0.8	40
36	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	1.8	39

#	ARTICLE	IF	CITATIONS
37	Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country. <i>Pediatric Blood and Cancer</i> , 2011, 56, 560-567.	0.8	36
38	Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. <i>British Journal of Haematology</i> , 2015, 170, 398-407.	1.2	34
39	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	2.5	34
40	Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 469-474.	0.4	33
41	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 785-790.	3.3	33
42	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021, 106, 1828-1838.	1.7	33
43	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	2.5	33
44	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351.	1.1	31
45	Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. <i>Annals of Hematology</i> , 2015, 94, 1319-1326.	0.8	30
46	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
47	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial. <i>Blood</i> , 2019, 134, 740-740.	0.6	30
48	Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. <i>British Journal of Haematology</i> , 2014, 166, 360-368.	1.2	27
49	Evaluation of <i>TP53</i> mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: Correlation with clinical outcome and gene expression profiling. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 263-274.	1.5	25
50	Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts. <i>British Journal of Haematology</i> , 2017, 178, 583-587.	1.2	23
51	Screening policies, preventive measures and in-hospital infection of COVID-19 in global surgical practices. <i>Journal of Global Health</i> , 2020, 10, 020507.	1.2	23
52	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1017-1024.	1.7	22
53	Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2015, 168, 305-308.	1.2	21
54	Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2017, 52, 473-475.	1.3	21

#	ARTICLE	IF	CITATIONS
55	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL1308 trial. <i>American Journal of Hematology</i> , 2021, 96, 292-301.	2.0	21
56	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. <i>American Journal of Hematology</i> , 2014, 89, 74-82.	2.0	20
57	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	0.8	20
58	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , 2018, 29, 966-972.	0.6	19
59	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020, 189, 853-859.	1.2	18
60	An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 481-489.	1.2	17
61	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinicobiological parameters. <i>British Journal of Haematology</i> , 2021, 193, 129-132.	1.2	17
62	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	1.3	17
63	How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy? a GIMEMA MPN WP survey. <i>Leukemia</i> , 2020, 34, 2805-2808.	3.3	16
64	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. <i>Leukemia</i> , 2020, 34, 2813-2814.	3.3	16
65	Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 936-937.	2.0	14
66	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	1.2	14
67	Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. <i>Haematologica</i> , 2020, 106, 39-45.	1.7	14
68	Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 125-131.	2.0	12
69	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020, 9, 8468-8479.	1.3	12
70	Association of Polygenic Risk Score and Bacterial Toxins at Screening Colonoscopy with Colorectal Cancer Progression: A Multicenter Case-Control Study. <i>Toxins</i> , 2021, 13, 569.	1.5	12
71	Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 424-429.	0.6	11
72	Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 331.e17-331.e23.	0.8	11

#	ARTICLE	IF	CITATIONS
73	First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014, 124, 797-797.	0.6	11
74	Blastic plasmocitoid dendritic cell neoplasm with leukemic spread: a GIMEMA survey. <i>Blood Advances</i> , 2021, 5, 5608-5611.	2.5	11
75	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	1.7	9
76	Biallelic <i>BIRC3</i> inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. <i>British Journal of Haematology</i> , 2019, 185, 156-159.	1.2	9
77	Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol. <i>Bone Marrow Transplantation</i> , 2019, 54, 1717-1720.	1.3	9
78	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	0.6	9
79	A Simple Clinical Prognostic Scoring System for Newly Diagnosed Cytogenetically Normal Acute Myeloid Leukemia: a Retrospective Analysis on 530 Patients. <i>Blood</i> , 2010, 116, 4848-4848.	0.6	9
80	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
81	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011, 52, 2329-2335.	0.6	7
82	Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. <i>Annals of Hematology</i> , 2021, 100, 1059-1063.	0.8	7
83	Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 1224-1233.	0.6	6
84	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial. <i>Blood</i> , 2021, 138, 3603-3603.	0.6	6
85	Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 37-38.	0.6	6
86	Comprehensive global collaboration in the care of 1182 pediatric oncology patients over 12 years: The Iraqi Italian experience. <i>Cancer Medicine</i> , 2023, 12, 256-265.	1.3	6
87	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2019, 84, 106191.	0.4	5
88	Deferasirox Chelation Therapy in Transfusion Dependent MDS Patients. Final Report From the Gimema MDS0306 Prospective Trial. <i>Blood</i> , 2012, 120, 425-425.	0.6	5
89	Concurrent search for unrelated cord and volunteer donor in high-risk acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2012, 91, 941-948.	0.8	4
90	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.4	4

#	ARTICLE	IF	CITATIONS
91	Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. <i>Leukemia</i> , 2018, 32, 543-546.	3.3	4
92	Diffusion-weighted magnetic resonance imaging in painful bone metastases: Using quantitative apparent diffusion coefficient as an indicator of effectiveness of single fraction versus multiple fraction radiotherapy. <i>European Journal of Radiology</i> , 2018, 98, 1-6.	1.2	4
93	Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 279-288.	0.6	4
94	Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia. <i>Leukemia Research</i> , 2020, 99, 106462.	0.4	4
95	Non- ϵ vert disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2021, 39, 423-427.	0.8	4
96	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients – a 25-year Italian experience. <i>British Journal of Haematology</i> , 2021, 195, 278-283.	1.2	4
97	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. <i>Blood</i> , 2012, 120, 2601-2601.	0.6	4
98	Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. <i>EJHaem</i> , 2022, 3, 121-128.	0.4	4
99	Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation. <i>Cancers</i> , 2021, 13, 1083.	1.7	3
100	Prognostic impact of $\text{KMT2A}^{\text{AFF1}}$ positivity in 926 $\text{BCR}^{\text{CABL1}}$ negative $\text{B}^{\text{lineage}}$ acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. <i>American Journal of Hematology</i> , 2021, 96, E334-E338.	2.0	3
101	Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center. <i>Leukemia and Lymphoma</i> , 2021, 62, 3430-3439.	0.6	3
102	Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408. , 2014, , .		3
103	Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Interim Analysis of the OITI Trial. <i>Blood</i> , 2019, 134, 1652-1652.	0.6	3
104	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	0.6	3
105	BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion. <i>Blood</i> , 2014, 124, 3295-3295.	0.6	3
106	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. <i>Blood Advances</i> , 2022, 6, 2510-2516.	2.5	3
107	Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	1.7	3
108	Clinical responses in allografted acute leukaemia patients with resistant disease using a combined chemo-immunotherapeutic treatment strategy. <i>British Journal of Haematology</i> , 2010, 151, 86-89.	1.2	2

#	ARTICLE	IF	CITATIONS
109	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. <i>Pharmacogenomics Journal</i> , 2018, 18, 444-449.	0.9	2
110	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.4	2
111	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. <i>Blood</i> , 2010, 116, 2471-2471.	0.6	2
112	NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment. <i>Blood</i> , 2012, 120, 1784-1784.	0.6	2
113	Variable Outcome of Allogeneic Stem Cell Transplant According to the Different Levels of Pre-Transplant Minimal Residual Disease, in Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3230-3230.	0.6	2
114	Feasibility of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study. <i>Blood</i> , 2015, 126, 66-66.	0.6	2
115	Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107). <i>Blood</i> , 2010, 116, 510-510.	0.6	2
116	Prognostic Impact of t(4;11)(q21;q23)/KMT2A-AFF1-Positivity in 926 BCR-ABL1-Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996. <i>Blood</i> , 2019, 134, 1469-1469.	0.6	2
117	The Validation of the BCR/ABL1-like Predictor across Laboratories Shows Reproducibility of Results. <i>Blood</i> , 2019, 134, 5211-5211.	0.6	2
118	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	2.5	2
119	Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2019, 102, 442-443.	1.1	1
120	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2020, 61, 979-982.	0.6	1
121	The COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges. <i>British Journal of Haematology</i> , 2020, 190, e211-e214.	1.2	1
122	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020, 105, 2671-2674.	1.7	1
123	Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2688-2688.	0.6	1
124	Incidence and Predictors of Early Treatment-Related Mortality In Pediatric Acute Lymphoblastic Leukemia In Baghdad (Iraq). <i>Blood</i> , 2010, 116, 2132-2132.	0.6	1
125	Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study. <i>Blood</i> , 2015, 126, 2946-2946.	0.6	1
126	5-Azacitidine, Valproic Acid and ALL-Trans Retinoic Acid in INT-2/High Risk Myelodysplastic Syndromes: Results of the GIMEMA MDS0205 Multicenter Trial. <i>Blood</i> , 2008, 112, 3648-3648.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 2359-2359.	0.6	1
128	CD34+CD38-CD117+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	0.6	1
129	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021, 138, 3746-3746.	0.6	1
130	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020, 136, 32-33.	0.6	1
131	5.10 Combination of Bendamustine and Ofatumumab (Bendofa) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: A Preliminary Report. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S248-S249.	0.2	0
132	Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S83-S84.	0.2	0
133	Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience. <i>British Journal of Haematology</i> , 2016, 173, 749-753.	1.2	0
134	AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance in the AMYNERVA-GIMEMA AML1919 trial. <i>Future Oncology</i> , 2021, 17, 3787-3796.	1.1	0
135	The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1). <i>Blood</i> , 2009, 114, 2618-2618.	0.6	0
136	Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial. <i>Blood</i> , 2010, 116, 2928-2928.	0.6	0
137	Immune Thrombocytopenia Associated to Low-Dose Alemtuzumab Therapy in Chronic Lymphocytic Leukemia: A Single Retrospective Center Experience. <i>Blood</i> , 2012, 120, 4598-4598.	0.6	0
138	Forest Plot to Compare Therapies in a Network Meta-Analysis in First Line Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4596-4596.	0.6	0
139	Age-Stratified Analysis Of The Prognostic Role Of Minimal Residual Disease Detection By Flow Cytometry, In Adult Patients With Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2649-2649.	0.6	0
140	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014, 124, 3265-3265.	0.6	0
141	Abstract 5491: Sequential use of first and second generation TKIs are effective on prolonged overall survival in elderly population affected by Ph+ acute lymphoblastic leukemia: the GIMEMA experience. , 2015, , .		0
142	Rapid Identification of BCR/ABL1-like Acute Lymphoblastic Leukemia (ALL) Cases By Quantitative Real Time-PCR (Q-RT-PCR). Generation and Validation of a Predictive Statistical Model. <i>Blood</i> , 2015, 126, 1410-1410.	0.6	0
143	Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1675-1675.	0.6	0
144	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. <i>Blood</i> , 2016, 128, 3240-3240.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Pattern of Central Nervous System (CNS) Involvement in Adult Acute Myeloid Leukemia (AML) and Its Impact on Outcome. <i>Blood</i> , 2016, 128, 2789-2789.	0.6	0
146	Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group. <i>Blood</i> , 2018, 132, 5634-5634.	0.6	0
147	Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters. <i>Blood</i> , 2019, 134, 5170-5170.	0.6	0
148	Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients. <i>Blood</i> , 2019, 134, 5083-5083.	0.6	0
149	Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 3755-3755.	0.6	0
150	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	0.6	0
151	Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
152	Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
153	Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	0.6	0
154	Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol. <i>Cancers</i> , 2022, 14, 3012.	1.7	0